STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Sera Prognostics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Sera Prognostics, Inc. (SERA) Form 144 notice reports a proposed sale of 1,458 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The filing shows an aggregate market value of $4,709.34 for the proposed sale and lists 37,094,109 shares outstanding. The shares to be sold were acquired as restricted stock units on 05/15/2024. The filer also reported three recent sales during the past three months by the same person totaling 18,313 shares for gross proceeds of $55,139.26 on 06/10/2025, 08/08/2025, and 08/29/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans a small RSU sale; recent 10b5-1 and voluntary sales suggest routine liquidity rather than a material governance event.

The filing documents a proposed sale of 1,458 shares derived from restricted stock units granted 05/15/2024. The planned transaction is being executed through Morgan Stanley Smith Barney LLC and shows a modest aggregate market value of $4,709.34 against 37,094,109 shares outstanding, indicating immaterial dilution or impact on market float. The filing also discloses multiple recent sales totaling 18,313 shares and $55,139.26 in proceeds, including one executed under a 10b5-1 plan, which typically signifies prearranged liquidity rather than opportunistic trading. No statements in the filing indicate undisclosed material nonpublic information.

TL;DR: Transactions are small relative to share count; unlikely to materially affect valuation or signal major insider shift.

The proposed sale size (1,458 shares, $4,709.34) is negligible versus the 37.09 million shares outstanding. Prior three-month dispositions of 18,313 shares produced $55,139.26, reflecting small-scale insider liquidity. The provenance of the shares (RSUs dated 05/15/2024) and the presence of a 10b5-1 sale reduce the likelihood that these trades convey new operational insights. From a market-impact perspective, these entries are routine and carry a neutral signal for investors when considered in isolation.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Latest News

SERA Latest SEC Filings

SERA Stock Data

130.45M
33.40M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY